PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy

  • End date
    Dec 31, 2024
  • participants needed
  • sponsor
    Institute of Hematology & Blood Diseases Hospital
Updated on 11 April 2023


This is a prospective, multicenter, single-arm, pilot study. The aim of this study is to evaluate the efficacy and safety of Linperlisib, the PI3K delta inhibitor for autoimmune hemolytic anemia patients who failed the second line therapy.

Condition Autoimmune Hemolytic Anemia, Failure of Two Rounds of Treatment
Treatment Linperlisib
Clinical Study IdentifierNCT05676697
SponsorInstitute of Hematology & Blood Diseases Hospital
Last Modified on11 April 2023


Yes No Not Sure

Inclusion Criteria

Male or female age ≥ 18 years
Diagnosis of primary warm antibody hemolytic anemia (AIHA)
Hemoglobin < 100g/L
Refractory to or relapsed after at least 2 prior treatment line
ECOG performance status ≤ 2
Willing and able to comply with the requirements for this study and written informed consent

Exclusion Criteria

Neutrophils counts < 0.5×10^9/L or platelet counts < 50 x 10^9/L
Diagnosis of any of the following diseases: Cold agglutinin disease, cold agglutinin syndrome, mixed AIHA, paroxysmal cold hemoglobinuria (PCH)
Diagnosis of the active stage of the connective tissue or systemic autoimmune rheumatic diseases (SARDs)
History of lymphoproliferative neoplasms
Had other inherited or acquired hemolytic diseases
Secondary AIHA caused by drugs or infection
Previously received organ or stem cell transplantation
Had malignant tumor within 5 years before enrollment, exclusive of cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial tumor, cervical carcinoma in situ or other indolent tumors
Patients with HBV, HCV, HIV or other infections that require treatment
Abnormal liver function: two consecutive examinations with an interval of ≥1 week suggest that ALT and AST are 2.5 times higher than the upper limit of normal values
Renal impairment: creatinine clearance <60ml/min
Any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study, including clinically significant cardiac diseases, refractory hypertension, metabolic disorders and other diseases that seriously affect the function of the gastrointestinal tract
Had a history of any psychiatric diseases, cerebrovascular disease or cognitive sequelae of head injury
Received rituximab in 6 weeks before enrollment
Received attenuated vaccine 4 in weeks before enrollment
Participation in another clinical trial within 4 weeks before the start of this trial
Have an allergy to Linperlisib or any other part of this medicine
Previously treated with other PI3Kδ inhibitor
Pregnant or breast-feeding patients
Patients considered to be ineligible for the study by the investigator for reasons other than the above
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note